Nomura initiated coverage of ChangXin Memory on its IPO day with a buy rating and a PT of 116 yuan. The bank said global memory-chip supply is unlikely to ease as quickly as consensus expects, which should accelerate ChangXin’s market-share gains. Nomura said capacity expansion, process upgrades and rising ASPs will drive rapid revenue and net income attributable to parent-company shareholders. The 116 yuan PT implies roughly 12.4x upside to the 8.66 yuan issue price; based on the pre-overallotm

Midday: Shanghai Composite +0.40%, Shenzhen Composite +1.41%, ChiNext +1.55%, Beijing Stock Exchange 50 +1.88%. Combined turnover on Shanghai/Shenzhen RMB 1.35 tln, up RMB 124.2 bln vs prior session. About 4,900 stocks advanced. ChangXin Technology’s STAR Market debut surged as much as 530% intraday; market cap reached RMB 3.61 tln, making it the largest A-share by market value, surpassing Intel’s July 24 close of $465.6 bln (~RMB 3.15 tln). Brain–computer interface names outperformed: Innovation Medical recorded two limit-ups in three sessions and Aipeng Medical hit a 20% daily limit. Battery sector extended gains: Shengyang, Wanli, Longpan Technology and Zijian Electronics hit daily limits; Lingpai Technology and Longxin Intelligent rose >10%. Innovative drug sector firmed: Ha Sanlian registered three limit-ups in four sessions; Hainan Haiyao and Yibai Pharmaceutical posted two limit-ups in four sessions. Oil & gas lagged: Zhongman Petroleum hit limit-down; Tongyuan Petroleum, Qianeng Hengxin and Keli fell >10%.

新加坡金管局：随时准备遏制新加坡元的过度波动。